Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

783
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
783
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

6.0K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
6.0K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.8K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

The New England journal of medicine·2019
Same author

Reply to Horowitz.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2017
Same author

Bezlotoxumab and Recurrent Clostridium difficile Infection.

The New England journal of medicine·2017
Same author

Bezlotoxumab - A New Agent for Clostridium difficile Infection.

The New England journal of medicine·2017
Same author

How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite.

Open forum infectious diseases·2016

Related Experiment Video

Updated: Feb 25, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Clostridium difficile Infection.

John G Bartlett1

  • 1Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 Orleans Street, Baltimore MD, 2128, USA.

Infectious Disease Clinics of North America
|August 7, 2017
PubMed
Summary

Clostridium difficile infection poses significant patient and economic burdens. Addressing this healthcare-associated complication is crucial for improving patient outcomes and reducing financial penalties for healthcare providers.

Keywords:
Centers for Disease Control and PreventionClostridium difficileIntensive care unitsWhite blood cell

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.3K

Area of Science:

  • Infectious Diseases
  • Healthcare Management
  • Public Health

Background:

  • Clostridium difficile infection (CDI) is a serious, often life-threatening complication of antibiotic therapy.
  • CDI presents substantial morbidity and mortality, impacting patient well-being.
  • Healthcare institutions face financial penalties due to CDI, as it is considered a preventable healthcare-associated infection.

Purpose of the Study:

  • To highlight the significant patient and economic consequences of Clostridium difficile infection.
  • To underscore the role of antibiotic treatment in iatrogenic CDI.
  • To emphasize the financial incentives for developing novel prevention and treatment strategies for CDI.

Main Methods:

  • Review of current literature on Clostridium difficile infection.
  • Analysis of patient and economic impacts of CDI.
  • Examination of healthcare policy implications related to CDI.

Main Results:

  • Clostridium difficile infection leads to severe patient outcomes and considerable economic strain on healthcare systems.
  • The Centers for Disease Control and Prevention classifies CDI as a healthcare-associated complication.
  • Financial penalties for healthcare providers incentivize the development of new CDI interventions.

Conclusions:

  • Effective prevention and treatment of Clostridium difficile infection are essential to mitigate patient harm and financial losses.
  • Addressing CDI requires a multi-faceted approach involving clinical practice and healthcare policy.
  • Further research and innovation are needed to combat this challenging healthcare-associated infection.